Abstract
No public abstract is available from the verified source records.
Holly Lee
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
unpaywall
Confidence 95%
datacite
Confidence 0%
No local citing links have been materialized yet.
MK-4002, a B-cell maturation antigen-targeting T-cell engager, in relapsed or refractory multiple myeloma: a first-in-human, open-label, phase 1 study
10.1016/s2352-3026(26)00228-0 · 2026
Teclistamab in relapsed or refractory multiple myeloma
10.1056/nejmoa2203478 · 2022
Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results
10.1038/s41591-023-02528-9 · 2023
Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial
10.1038/s41591-023-02589-w · 2023
Linvoseltamab in patients with relapsed/refractory multiple myeloma in the LINKER-MM1 study: longer follow-up and subgroup analyses
10.1016/j.clml.2025.11.004 · 2026
Cytokine release syndrome and cancer immunotherapies – historical challenges and promising futures
10.3389/fimmu.2023.1190379 · 2023
Preclinical and nonclinical characterization of HPN217: a tri-specific t cell activating construct (TriTAC) targeting B cell maturation antigen (BCMA) for the treatment of multiple myeloma
2018
Bispecific antibodies: advancing precision oncology
10.1016/j.trecan.2024.07.002 · 2024
Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma
10.1038/s41591-023-02491-5 · 2023
No additional external references are available.